Soleno Therapeutics, Inc. (NASDAQ:SLNO) has announced its intention to offer and sell shares of its common stock and/or pre-funded warrants in an underwritten public offering. The company also plans to grant underwriters a 30-day option to purchase additional shares equal to 15% of the aggregate number of shares sold in the public offering. Concurrently, Soleno intends to enter into a securities purchase agreement with certain investors for up to $30 million of shares at the public offering price. The completion of the private placement is contingent upon the closing of the public offering. Guggenheim Securities, LLC, Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. are acting as the joint book-running managers for the public offering and placement agents for the private placement.